Type 1 diabetes (T1D) typically shows almost no initial symptoms, and approximately 90% have already progressed to Stage 3 with clear clinical symptoms by the time of diagnosis. With the approval of Tzield in 2022, early diagnosis and intervention at Stage 2 have become increasingly important, as timely treatment can delay disease onset and reduce the risk of severe progression. To address this challenge, the company combines genetic risk-prediction technology with a fully online screening program to enable detection at Stage 2 or earlier. This approach allows the early identification of undiagnosed high-risk individuals and provides them with meaningful opportunities for timely intervention.